Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,800 matching trials from the live ClinicalTrials.gov search.
Conditions
Renal Cell Carcinoma
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Omaha, Nebraska • Hackensack, New Jersey • Houston, Texas
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab
Other · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Kidney Neoplasm
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Conditions
Renal Cell Cancer
Interventions
Sunitinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Kidney Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
radiofrequency ablation, thermal ablation therapy
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Breast Cancer, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Prostate Cancer, Bladder Cancer
Interventions
Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years to 111 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Kidney Cancer
Interventions
bevacizumab
Biological
Lead sponsor
Paul Monk
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Carcinoma, Renal Cell
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Terminated Not applicable Interventional Results available

Treatment Resistance Following Anti-cancer Therapies

NCT04436120
Conditions
Disease Progression
Interventions
De novo tumor tissue biopsy, Research blood draws
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 10 more
Conditions
Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma, Melanoma
Interventions
second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Years to 26 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Renal Cell Cancer
Interventions
Bevacizumab and Bortezomib
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Advanced Solid Tumors
Interventions
ALT-803
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Minneapolis, Minnesota • Lebanon, New Hampshire • New Brunswick, New Jersey + 2 more
Conditions
Carcinoma, Renal Cell Metastasis
Interventions
SU011248 (sunitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Stanford, California • Las Vegas, Nevada
Conditions
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
Interventions
XmAb20717
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Conditions
Kidney (Renal Cell) Cancer
Interventions
dTA/dBA C-arm fluoroscopy system with Dyna CT, DSA arteriogram- hepatic arteries, CO2 aortogram
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Metastatic Renal Cell Cancer
Interventions
perfusion computed tomography
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Stanford, California
Conditions
Advanced Malignancies
Interventions
MBG453, PDR001, Decitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more
Conditions
Breast Neoplasms, Lung Neoplasms, Cancer of Liver, Lymphoma, Cancer of Kidney
Interventions
Metformin XR, Delayed Metformin, Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated), Atypical Teratoid/Rhabdoid Tumor, Other INI1 Negative Tumors (With PI Approval), Other SMARCA4-deficient Malignant Tumors (With PI Approval)
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
6 Months to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Conditions
Carcinoma, Renal Cell, Melanoma
Interventions
GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • Cambridge, Massachusetts + 2 more
Conditions
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
Interventions
Durvalumab, Therapeutic Conventional Surgery, Tremelimumab
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Radiation Therapy, Cancer, Cancer of Anus, Cancer of Bladder, Cancer of Cervix, Cancer of Colon, Cancer of Rectum, Cancer of Esophagus, Cancer of Gallbladder, Cancer of Liver, Cancer of Ovary, Cancer of Pancreas, Cancer of Prostate, Cancer of Kidney and Renal Pelvis, Cancer of Stomach, Cancer of Testis, Cancer of Uterus, Cancer of Uterus and Cervix, Cancer of Kidney
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Compton, California • Bradenton, Florida • Fort Myers, Florida + 1 more
Conditions
Kidney Cancer
Interventions
pegylated interferon alfa
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
2
States / cities
Los Angeles, California • New York, New York